BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

244 related articles for article (PubMed ID: 25904753)

  • 1. Promoter Methylation of CDO1 Identifies Clear-Cell Renal Cell Cancer Patients with Poor Survival Outcome.
    Deckers IA; Schouten LJ; Van Neste L; van Vlodrop IJ; Soetekouw PM; Baldewijns MM; Jeschke J; Ahuja N; Herman JG; van den Brandt PA; van Engeland M
    Clin Cancer Res; 2015 Aug; 21(15):3492-500. PubMed ID: 25904753
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A Four-Gene Promoter Methylation Marker Panel Consisting of
    van Vlodrop IJH; Joosten SC; De Meyer T; Smits KM; Van Neste L; Melotte V; Baldewijns MMLL; Schouten LJ; van den Brandt PA; Jeschke J; Yi JM; Schuebel KE; Ahuja N; Herman JG; Aarts MJ; Bosman FT; Van Criekinge W; van Engeland M
    Clin Cancer Res; 2017 Apr; 23(8):2006-2018. PubMed ID: 27756787
    [No Abstract]   [Full Text] [Related]  

  • 3. CDO1 promoter methylation is associated with gene silencing and is a prognostic biomarker for biochemical recurrence-free survival in prostate cancer patients.
    Meller S; Zipfel L; Gevensleben H; Dietrich J; Ellinger J; Majores M; Stein J; Sailer V; Jung M; Kristiansen G; Dietrich D
    Epigenetics; 2016 Dec; 11(12):871-880. PubMed ID: 27689475
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Development of a prognostic risk model for clear cell renal cell carcinoma by systematic evaluation of DNA methylation markers.
    Joosten SC; Odeh SNO; Koch A; Buekers N; Aarts MJB; Baldewijns MMLL; Van Neste L; van Kuijk S; Schouten LJ; van den Brandt PA; Tjan-Heijnen VC; van Engeland M; Smits KM
    Clin Epigenetics; 2021 May; 13(1):103. PubMed ID: 33947447
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prognostic significance of promoter DNA hypermethylation of the cysteine dioxygenase 1 (CDO1) gene in primary gallbladder cancer and gallbladder disease.
    Igarashi K; Yamashita K; Katoh H; Kojima K; Ooizumi Y; Nishizawa N; Nishiyama R; Kawamata H; Tajima H; Kaizu T; Kumamoto Y; Watanabe M
    PLoS One; 2017; 12(11):e0188178. PubMed ID: 29161283
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Differential Prognostic Relevance of Promoter DNA Methylation of
    Tanaka Y; Kosaka Y; Waraya M; Yokota K; Harada H; Kaida T; Kikuchi M; Minatani N; Nishimiya H; Katoh H; Sengoku N; Watanabe M; Yamashita K
    Anticancer Res; 2019 May; 39(5):2289-2298. PubMed ID: 31092420
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prognostic Significance of Promoter DNA Hypermethylation of cysteine dioxygenase 1 (CDO1) Gene in Primary Breast Cancer.
    Minatani N; Waraya M; Yamashita K; Kikuchi M; Ushiku H; Kojo K; Ema A; Nishimiya H; Kosaka Y; Katoh H; Sengoku N; Tanino H; Sidransky D; Watanabe M
    PLoS One; 2016; 11(1):e0144862. PubMed ID: 26785325
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cancer-specific promoter DNA methylation of Cysteine dioxygenase type 1 (CDO1) gene as an important prognostic biomarker of gastric cancer.
    Harada H; Hosoda K; Moriya H; Mieno H; Ema A; Ushiku H; Washio M; Nishizawa N; Ishii S; Yokota K; Tanaka Y; Kaida T; Soeno T; Kosaka Y; Watanabe M; Yamashita K
    PLoS One; 2019; 14(4):e0214872. PubMed ID: 30934021
    [TBL] [Abstract][Full Text] [Related]  

  • 9. CDO1 promoter methylation is a biomarker for outcome prediction of anthracycline treated, estrogen receptor-positive, lymph node-positive breast cancer patients.
    Dietrich D; Krispin M; Dietrich J; Fassbender A; Lewin J; Harbeck N; Schmitt M; Eppenberger-Castori S; Vuaroqueaux V; Spyratos F; Foekens JA; Lesche R; Martens JW
    BMC Cancer; 2010 Jun; 10():247. PubMed ID: 20515469
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Methylated promoter DNA of CDO1 gene and preoperative serum CA19-9 are prognostic biomarkers in primary extrahepatic cholangiocarcinoma.
    Nakamoto S; Kumamoto Y; Igarashi K; Fujiyama Y; Nishizawa N; Ei S; Tajima H; Kaizu T; Watanabe M; Yamashita K
    PLoS One; 2018; 13(10):e0205864. PubMed ID: 30325974
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Diagnostic potential of hypermethylation of the cysteine dioxygenase 1 gene (CDO1) promoter DNA in pancreatic cancer.
    Nishizawa N; Harada H; Kumamoto Y; Kaizu T; Katoh H; Tajima H; Ushiku H; Yokoi K; Igarashi K; Fujiyama Y; Okuwaki K; Iwai T; Watanabe M; Yamashita K
    Cancer Sci; 2019 Sep; 110(9):2846-2855. PubMed ID: 31325200
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prediction of Efficacy of Postoperative Chemotherapy by DNA Methylation of CDO1 in Gastric Cancer.
    Harada H; Soeno T; Yokoi K; Nishizawa N; Ushiku H; Hosoda K; Hiki N; Yamashita K
    J Surg Res; 2020 Dec; 256():404-412. PubMed ID: 32777557
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Promoter DNA methylation of CDO1 gene and its clinical significance in esophageal squamous cell carcinoma.
    Ushiku H; Yamashita K; Katoh H; Ema A; Minatani N; Kikuchi M; Kojo K; Yokoi K; Tanaka T; Nishizawa N; Ishii S; Hosoda K; Moriya H; Mieno H; Katada N; Kikuchi S; Watanabe M
    Dis Esophagus; 2017 Feb; 30(2):1-9. PubMed ID: 27629777
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The clinical significance of cysteine dioxygenase type 1 methylation in Barrett esophagus adenocarcinoma.
    Kojima K; Yamashita K; Ushiku H; Katoh H; Ishii S; Tanaka T; Yokoi K; Suzuki M; Ooizumi Y; Igarashi K; Hosoda K; Moriya H; Mieno H; Katada N; Tanabe S; Watanabe M
    Dis Esophagus; 2017 Mar; 30(3):1-9. PubMed ID: 28184414
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prognostic significance of Gremlin1 (GREM1) promoter CpG island hypermethylation in clear cell renal cell carcinoma.
    van Vlodrop IJ; Baldewijns MM; Smits KM; Schouten LJ; van Neste L; van Criekinge W; van Poppel H; Lerut E; Schuebel KE; Ahuja N; Herman JG; de Bruïne AP; van Engeland M
    Am J Pathol; 2010 Feb; 176(2):575-84. PubMed ID: 20042676
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A Two-DNA Methylation Signature to Improve Prognosis Prediction of Clear Cell Renal Cell Carcinoma.
    Shi S; Ye S; Wu X; Xu M; Zhuo R; Liao Q; Xi Y
    Yonsei Med J; 2019 Nov; 60(11):1013-1020. PubMed ID: 31637882
    [TBL] [Abstract][Full Text] [Related]  

  • 17. DNA methylation of the SLC16A3 promoter regulates expression of the human lactate transporter MCT4 in renal cancer with consequences for clinical outcome.
    Fisel P; Kruck S; Winter S; Bedke J; Hennenlotter J; Nies AT; Scharpf M; Fend F; Stenzl A; Schwab M; Schaeffeler E
    Clin Cancer Res; 2013 Sep; 19(18):5170-81. PubMed ID: 23881922
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Methylated cysteine dioxygenase-1 gene promoter in the serum is a potential biomarker for hepatitis B virus-related hepatocellular carcinoma.
    Yang Y; Fan YC; Gao S; Dou CY; Zhang JJ; Sun FK; Wang K
    Tohoku J Exp Med; 2014 Mar; 232(3):187-94. PubMed ID: 24646840
    [TBL] [Abstract][Full Text] [Related]  

  • 19. DNA methylation status defines clinicopathological parameters including survival for patients with clear cell renal cell carcinoma (ccRCC).
    Evelönn EA; Degerman S; Köhn L; Landfors M; Ljungberg B; Roos G
    Tumour Biol; 2016 Aug; 37(8):10219-28. PubMed ID: 26831665
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Validation of DAB2IP methylation and its relative significance in predicting outcome in renal cell carcinoma.
    Wang ZR; Wei JH; Zhou JC; Haddad A; Zhao LY; Kapur P; Wu KJ; Wang B; Yu YH; Liao B; He DL; Chen W; Margulis V; Hsieh JT; Luo JH
    Oncotarget; 2016 May; 7(21):31508-19. PubMed ID: 27129174
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.